, Volume 5, Issue 2, pp 65-66
Date: 01 Apr 2009

Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access